FIGO staging: Definition, Uses, and Clinical Overview

FIGO staging Introduction (What it is)

FIGO staging is a standardized way to describe how far certain gynecologic cancers have spread.
It is published by the International Federation of Gynecology and Obstetrics (FIGO).
Clinicians use it most often for cancers of the cervix, uterus (endometrium), ovary/fallopian tube, vulva, and vagina.
It helps teams speak a common “stage language” when planning care and discussing outcomes.

Why FIGO staging used (Purpose / benefits)

Cancer care depends on clearly answering a few core questions: Where did the cancer start, how large is it, and has it spread beyond the organ of origin? Without a shared staging system, different hospitals and clinicians could describe the same situation in different ways, making treatment planning and communication harder.

FIGO staging solves this by providing a consistent framework to classify disease extent for many gynecologic cancers. While the exact criteria vary by cancer site (for example, cervix versus ovary), the overall goals are similar:

• Support accurate diagnosis and extent-of-disease assessment by organizing clinical, imaging, and pathology findings into a stage category.
• Guide treatment planning by helping teams align care with typical stage-based approaches (for example, local therapy vs systemic therapy), recognizing that plans still vary by clinician and case.
• Improve communication among gynecologic oncologists, radiation oncologists, medical oncologists, radiologists, pathologists, and primary care clinicians.
• Enable clearer patient education by offering a structured way to explain what “early” versus “advanced” disease means in practical terms.
• Standardize research and quality measurement so clinical trials and outcomes reporting can compare similar groups (often called “apples to apples” comparisons).
• Assist prognostic discussions in broad terms, while acknowledging that prognosis varies by cancer type, tumor biology, and response to treatment.

Indications (When oncology clinicians use it)

Clinicians typically apply FIGO staging in situations such as:

• A new diagnosis of a gynecologic cancer (cervical, endometrial/uterine, ovarian/fallopian tube, vulvar, vaginal, and some related gynecologic malignancies)
• A suspicious biopsy result from the cervix, uterus, ovary, vulva, or vagina that needs full extent-of-disease workup
• Pre-treatment planning for surgery, radiation therapy, and/or systemic therapy (chemotherapy, targeted therapy, immunotherapy), depending on the cancer type
• Multidisciplinary tumor board review, where consistent staging supports team decision-making
• Enrollment into a clinical trial where eligibility or stratification depends on stage
• Documentation for cancer registries and outcomes reporting

Contraindications / when it’s NOT ideal

FIGO staging is not a universal staging system for all cancers, and it may be less suitable in certain contexts:

• Non-gynecologic cancers (for example, colorectal, breast, lung) are typically staged with other systems (often TNM-based), not FIGO staging.
• Hematologic malignancies (leukemia, lymphoma, myeloma) use different frameworks (for example, Ann Arbor for many lymphomas), so FIGO staging is not applicable.
• Incomplete diagnostic information, such as limited imaging, unavailable pathology details, or fragmented records, can make staging uncertain or provisional.
• Uncommon tumor types where FIGO staging is not the primary standard or where staging rules are less well established; clinicians may rely more heavily on tumor-specific guidelines.
• Situations where treatment begins before full staging is possible, such as urgent symptom management; staging may be refined later as additional information becomes available.
• Resource-limited settings where advanced imaging or specialized pathology is not accessible; clinicians may use the best available clinical staging approach and clearly document limitations.

How it works (Mechanism / physiology)

FIGO staging is a classification system, not a therapy, so it does not have a “mechanism of action” in the way a drug or procedure does. The closest relevant concept is its clinical pathway: it integrates findings from evaluation and testing to assign a stage category that reflects disease extent.

At a high level, FIGO staging relies on understanding:

• Anatomy of the female reproductive tract (cervix, uterus, ovaries/fallopian tubes, vagina, vulva) and how cancers typically extend locally.
• Patterns of tumor spread, which may include:
• Local invasion into nearby tissues and organs
• Lymphatic spread to regional lymph nodes (pelvic and/or para-aortic, depending on cancer type)
• Distant spread (metastasis) to organs outside the pelvis (varies by cancer type and case)

Many gynecologic cancers use a stage grouping concept that broadly aligns with:

• Stage I: confined to the organ of origin
• Stage II: extends beyond the organ but remains relatively localized (definitions vary)
• Stage III: regional spread (often including lymph nodes and/or broader local-regional extension)
• Stage IV: distant spread and/or involvement of specific distant organs (criteria vary)

Onset, duration, and reversibility: FIGO staging describes the cancer’s extent at the time of staging. It is typically recorded at diagnosis or initial treatment planning. The patient’s condition can change with treatment (response, remission, recurrence), but the originally assigned stage usually remains a reference point in the medical record; clinicians may clarify or update staging documentation if new information changes the understanding of disease extent.

FIGO staging Procedure overview (How it’s applied)

FIGO staging is not a single procedure. It is the result of a workflow that combines clinical evaluation, imaging, tissue diagnosis, and sometimes surgical findings. The exact steps vary by cancer type and clinical setting, but a general pathway often looks like this:

1. Evaluation / exam – Medical history (symptoms, bleeding patterns, pelvic pain, urinary or bowel symptoms) – Pelvic examination and relevant speculum or bimanual exam findings – Review of prior screening or diagnostic tests (for example, cervical screening history), when applicable

2. Imaging / biopsy / labs – Biopsy to confirm cancer type and key pathology features – Imaging to assess local extent and possible spread (modality varies by clinician and case) – Selected blood tests and tumor markers when clinically relevant (varies by cancer type)

3. Staging assignment – Clinicians synthesize clinical, imaging, and pathology data into the appropriate FIGO staging category for that cancer site. – Documentation typically includes both the stage group and any relevant substage details.

4. Treatment planning – Multidisciplinary discussion may include gynecologic oncology, radiation oncology, medical oncology, radiology, pathology, nursing, and supportive care. – The plan considers stage along with tumor subtype, grade, patient health status, and patient preferences.

5. Intervention / therapy – May include surgery, radiation therapy, systemic therapy, or combined approaches depending on the cancer type and stage.

6. Response assessment – Follow-up visits and repeat imaging or exams (when needed) evaluate treatment response and detect recurrence.

7. Follow-up / survivorship – Long-term surveillance plans address late effects, symptom management, sexual health, fertility considerations when relevant, and psychosocial support.

Types / variations

FIGO staging is applied across several gynecologic cancer sites, and the “type” of FIGO staging usually refers to which cancer is being staged and what information is used to stage it.

Common variations include:

• By cancer site (site-specific FIGO staging)
• Cervical cancer
• Endometrial (uterine) cancer
• Ovarian and fallopian tube cancers (often grouped closely)
• Vulvar cancer

• Vaginal cancer
  Each site has distinct criteria because patterns of spread and clinically relevant anatomic landmarks differ.

• Clinical vs surgical-pathologic emphasis

• Some cancers and settings rely heavily on clinical examination and imaging.

• Others rely substantially on surgical findings and pathology (for example, information from hysterectomy specimens or lymph node assessment), depending on clinician judgment and case factors.

• Imaging- and pathology-informed staging (modern practice patterns)

• In many care settings, imaging and pathology details refine stage assignment and help clarify lymph node involvement or distant disease, when those tests are performed and available.

• Care setting variation (outpatient vs inpatient)

• Staging workup may occur mostly outpatient (clinic visits, imaging, biopsies) or incorporate inpatient elements when surgery or urgent symptom management is needed.

• Adult vs pediatric

• FIGO staging is primarily used in adult gynecologic oncology. Pediatric and adolescent gynecologic tumors may be approached with additional pediatric oncology frameworks, depending on tumor type.

Pros and cons

Pros:

• Provides a shared, standardized language for gynecologic cancer extent
• Supports coordinated multidisciplinary care and clearer handoffs between clinicians
• Helps guide treatment planning in stage-informed ways (while still individualized)
• Facilitates research comparisons and clinical trial eligibility grouping
• Improves clarity for documentation in registries and medical records
• Can help patients understand “where the cancer is” in a structured way

Cons:

• Stage definitions vary by cancer site, so “Stage II” does not mean the same thing across all gynecologic cancers
• Staging accuracy depends on test quality and completeness (imaging, pathology, surgical assessment)
• Some cases remain uncertain or borderline, requiring specialist review and sometimes revision
• Access differences (imaging, specialized pathology, gynecologic oncology) can affect how confidently staging is assigned
• Stage does not fully capture tumor biology (molecular features, grade, histology) that can strongly affect treatment choices and outcomes
• Patients may assume stage alone predicts outcomes; in reality, prognosis varies by cancer type and stage and other factors

Aftercare & longevity

Because FIGO staging is not a treatment, “aftercare” focuses on what typically happens after staging and initial treatment planning, and what influences longer-term outcomes.

Factors that commonly affect outcomes and longevity in gynecologic cancers include:

• Cancer type and FIGO stage at diagnosis, which influence how localized or widespread disease is
• Tumor biology and pathology features, such as histologic subtype and grade (when applicable)
• Treatment approach and completeness, which may include combinations of surgery, radiation therapy, and systemic therapy (varies by clinician and case)
• Response to treatment, including how well the cancer shrinks or remains controlled
• Follow-up and surveillance, which may involve scheduled visits, exams, and selected tests to monitor for recurrence or late effects
• Supportive care and rehabilitation, such as pelvic floor therapy, lymphedema care when relevant, sexual health support, pain and symptom management, and psychosocial services
• Other health conditions (comorbidities) and overall physical functioning, which can affect treatment tolerance and recovery
• Access to care, including specialty services, transportation, financial support resources, and survivorship programs

In survivorship, many patients benefit from a clear summary of their diagnosis (including FIGO stage), treatments received, and a follow-up plan. The exact follow-up schedule and testing vary by cancer type, stage, and local practice.

Alternatives / comparisons

FIGO staging is a staging framework, so “alternatives” typically mean other ways of classifying extent of disease or other decision frameworks used alongside stage.

Common comparisons include:

• FIGO staging vs TNM (AJCC/UICC)
• TNM describes Tumor size/extent (T), lymph Nodes (N), and Metastasis (M) across many cancers.
• FIGO staging is designed specifically for gynecologic cancers and often aligns conceptually with TNM, but it is organized in FIGO stage groupings and site-specific rules.

• Many clinicians document both, depending on local reporting requirements.

• FIGO staging vs “grade” and molecular classification

• Stage describes where the cancer is.
• Grade and molecular features describe how the cancer cells look and behave.

• Modern care often uses both because patients with the same FIGO stage can have different risk profiles (varies by cancer type).

• FIGO staging vs observation/active surveillance

• Observation is a management approach, not a staging method.

• In select low-risk situations (depending on tumor type and clinician judgment), observation may be considered after diagnostic workup; stage still helps define whether that approach is reasonable.

• FIGO staging in treatment comparisons (surgery vs radiation vs systemic therapy)

• Stage frequently influences which modalities are discussed (local vs regional vs systemic approaches).

• However, treatment selection also depends on tumor subtype, patient health, fertility goals when relevant, and local expertise—so stage is necessary but not sufficient.

• Standard care vs clinical trials

• Clinical trials often use FIGO stage as an eligibility criterion or to stratify participants.
• Trials may offer access to new combinations or sequences of therapies, with potential benefits and uncertainties that are discussed during informed consent.

FIGO staging Common questions (FAQ)

Q: Is FIGO staging the same as “cancer grade”?
No. FIGO staging describes how far the cancer has spread in the body. Grade describes how abnormal the cancer cells look under a microscope and can relate to how the tumor may behave. Many treatment plans consider both.

Q: Does FIGO staging require surgery?
Not always. Depending on the cancer type and clinical situation, staging may be based on a combination of exam, imaging, and biopsy results, and sometimes surgical-pathology findings. Whether surgery is used for staging varies by clinician and case.

Q: Is FIGO staging painful?
The staging label itself is not painful, but tests used to determine stage can cause discomfort. Pelvic exams may feel uncomfortable, biopsies can cause brief pain or cramping, and imaging tests may involve IV contrast or long periods of stillness. Experiences vary by person and test type.

Q: Will I need anesthesia for FIGO staging?
FIGO staging is not a procedure, so anesthesia is not inherently required. Some diagnostic steps that inform staging (such as certain biopsies or surgical procedures) may use local anesthesia, sedation, or general anesthesia depending on what is being done. Your care team typically explains this before any procedure.

Q: How long does staging take?
The time needed varies by cancer type, how quickly imaging and pathology results return, and whether additional procedures are required. Some people receive a preliminary stage soon after initial testing, with refinements after more information is available. Timing also depends on local scheduling and resources.

Q: Does a higher FIGO stage always mean worse outcomes?
In general, more advanced stage often reflects more extensive disease, but outcomes are not determined by stage alone. Tumor biology, treatment options, response to therapy, and overall health can strongly influence prognosis. Many clinicians discuss prognosis as a range that varies by cancer type and stage.

Q: What does FIGO stage mean for treatment options?
Stage helps clinicians decide whether treatment is likely to focus on local control (for example, surgery and/or radiation) or include systemic therapy (for example, chemotherapy, targeted therapy, immunotherapy), depending on the cancer type. It does not dictate a single “correct” plan. Final decisions incorporate pathology details, patient health status, and patient goals.

Q: Are there side effects from FIGO staging?
The staging classification has no side effects, but the tests used to determine stage can. Possible issues include temporary bleeding after biopsy, contrast reactions in imaging (uncommon), or recovery effects if surgery is part of evaluation. The specific risk profile depends on the tests performed.

Q: What does FIGO staging mean for work and daily activity?
Staging itself does not limit activity, but appointments, procedures, and treatment planning can affect schedules and energy levels. If biopsies or surgery are performed, there may be temporary restrictions that vary by procedure and clinician preferences. Many people benefit from planning for time off around procedures and early treatment visits.

Q: Can FIGO staging affect fertility and pregnancy planning?
FIGO stage can influence which treatments are considered, and some treatments can affect fertility. Fertility preservation is a specialized topic that depends on cancer type, stage, tumor features, and timing. Patients who wish to preserve fertility often ask early for referral to specialists familiar with fertility-sparing options, when clinically appropriate.

Q: Will my FIGO stage change over time?
Stage is generally intended to describe the extent of disease at diagnosis or initial treatment planning. Your cancer status can change with treatment (response, remission, recurrence), but clinicians often continue to reference the original stage while also documenting current disease status. If new information substantially changes the understanding of disease extent, records may be clarified accordingly.